Cipher Reports Strong Q2 2012 Financial Results

Cipher Reports Strong Q2 2012 Financial Results
"Revenue from Lipofen® was solid and we had early contributions from our once-daily tramadol product which is now marketed both in the U.S. and Canada as ConZip® and Durela™. With the pending launch of Absorica™ in Q4 of this year, we will have …

Full News here – Read more on Equities.com

Leave a Reply